Authors

Longbo Li, Lei Zhao, Zhihui Wang, Lijuan Chen, Zhibo Li, Xiaohui Chen, Yan Li, Ning Zhao, Yuzhe Liu, Bin Liu#

Departments

Department of Cardiology, Second Hospital of Jilin University, Changchun,130000, China

Abstract

Objective: Drug eluting stent (DES) can significantly reduce the incidence of vascular restenosis. However, the efficacy of DES in the treatment of small vessel diseases needs further exploration. We conducted this retrospective study to evaluate the efficacy of drug coated balloon (DCB) in small vessel de novo lesions. 

Methods: This study was a retrospective non-randomized trial. 167 patients with small vessel diseases were enrolled in the research. The vessels involved in small vessel diseases are arteries with a diameter of less than 2.8mm. The occurrence of major adverse cardiac events (MACE) was assessed within 6 months after treatment.

Results: At the Second Hospital of Jilin University, 167 patients (177 lesions) with small vessel diseases were randomly selected from patients who received DCB treatment from April 2014 to April 2017. There was no statistically significant difference on minimal lumen diameter (MLD) between post-procedure and angiographic follow-up (1.28 ± 0.45 mm vs. 1.30 ± 0.24 mm, P=0.756). The late lumen loss was only 0.02 ± 0.41 mm. The lumen increase was found in 15 lesions, with the late lumen gain of 0.31 ± 0.39 mm in this subgroup. 2 patients developed restenosis and the incidence of restenosis was 6.5%. Myocardial infarction (not related to lesions) occurred in 3 patients and target lesion revascularization in 3 patients. The incidence of MACE was only 5.6% (n=7). 

Conclusion: DCB was shown to be safe and effective in the treatment of small vessel diseases and was able to increase the inner diameter of vascular lumen. A DCB-only approach might be an alternative strategy to DES.

Keywords

Drug coated balloon, restenosis, small vessel disease.

DOI:

10.19193/0393-6384_2019_6_555